DOCKET NO.: CP368 US Application No.: 10/597,977

Response to Office Action dated July 1, 2010

REMARKS

Applicants respectfully request entry of the enclosed amendment and consideration of the following remarks.

Claim Status

Claims 1, 6, 10-12, 14, 15, and 47 are amended. Claims 3, 7-9, 13, 16-18, 20-34, 38-46, 53 and 54 are cancelled without disclaimer or prejudice. Claims 4, 5, and 35-37 are previously presented. Claims 2 and 48-52 were previously cancelled. Claim 36 is original. Claims 56 through 59 are new.

No new matter is added by the enclosed amendment.

To advance the prosecution of the present application, Claim 1 is amended to provide various characterizing aspects of a particular crystalline form of Compound I, denoted in the specification as the alpha form. See, for example, page 2, lines 11-16 of the specification as originally filed and claim 3 (now cancelled). Claim 10 is amended to provide various characterizing aspects of a particular crystalline form of Compound I, denoted in the specification as the gamma form. See, for example, page 2, lines 23-28 of the specification as originally filed. Claim 14 is amended to provide various characterizing aspects of a particular crystalline form of Compound I, denoted in the specification as the delta form. See, for example, page 2, line 29 through page 3, line 2 of the specification as originally filed.

Claim 6 is amended to correct a typographical error in the space group designation $(P2_12_12_1)$ for the alpha crystalline form of Compound I.

Support for Claim 55 can be found throughout the specification as originally filed such as, for example, on page 2, line 29 through page 3, line 2.

Support for Claims 56 through 59 can be found throughout the specification as originally filed such as, for example, on page 14, line 18 through page 15, line 26.

DOCKET NO.: CP368 US PATENT

Application No.: 10/597,977

Response to Office Action dated July 1, 2010

CONCLUSION

As described above, claims 1, 4-6, 10-12, 14, and 15 have been rewritten in the manner

prescribed by the Examiner in the Final Action and therefore should now be allowable. It follows

that any claims directly or indirectly depending from or otherwise incorporating the subject

 $matter\ of\ these\ claims,\ i.e.,\ claims\ 19,47,47,55,\ and\ 56\ through\ 59,\ should\ also\ be\ allowable.$

Claims 35-37 were identified as allowable/allowed in the Final Action. Accordingly, all of the

pending claims are in condition for allowance.

With the entry of the enclosed amendment, it is respectfully submitted that the present

application and claims are in condition for allowance. The Examiner is invited to telephone the

undersigned attorney with any questions or to discuss any further issues in connection with the

prosecution of this application.

Respectfully submitted,

Date: December 9, 2010

/Rona A. Nardone / Rona A. Nardone

Reg. No. 55,481

CEPHALON, Inc. 41 Moores Road PO Box 4011

Frazer, PA 19355 Telephone: 610-727-6328

Telefax: 610-727-7651

- 9 -